Therapeutic Potential of Iron Chelators in Cancer Therapy

Publisher Website
Google Scholar
Abstract
The development of iron (Fe) chelators for clinical use remains an active research goal. Over the last thirty years desferrioxamine (DFO; DesferalR; Fig. 1) has been the drug of choice in the treatment of Fe overload disease.I’2Despite its considerable success, the problems with this drug remain significant and much research has been invested to obtain alternative ligands (see Chapters 7-9, 13, 14). At present, a number of potential chelators that are orally effective are available for experimental testing (see Chapters 7,13,14). Hence, one can envisage that in the future some of these compounds used alone or in various combinations may provide a better regimen than DFO.